C4X Discovery Holdings PLC Exercise of Options and Issue of Equity (6694E)
October 19 2018 - 11:33AM
UK Regulatory
TIDMC4XD
RNS Number : 6694E
C4X Discovery Holdings PLC
19 October 2018
C4X Discovery Holdings plc
("C4XD" or the "Company")
Exercise of Options
Issue of Equity
19 October 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces it has today issued
26,875 new ordinary shares of 1p each in the Company ("New Ordinary
Shares") following the exercise of options by a former employee of
the Company .
Application has been made for the New Ordinary Shares to be
admitted to trading on AIM and dealings are expected to commence on
or around 8.00 a.m. on 26 October 2018.
The New Ordinary Shares rank pari passu with the existing shares
of the Company. Following the issue of the New Ordinary Shares, the
Company's issued share capital now consists of 57,792,636 ordinary
shares. Accordingly, the figure of 57,792,636 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Consilium Strategic Communications 020 3709 5700
Mary-Jane Elliott, Matthew Neal, Chris Gardner
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is
primarily focused on the high value therapeutic areas of
inflammation, neurodegeneration and cancer (including
immuno-oncology) with a number of new drug candidates identified
and further progress made towards pre-clinical licensing
discussions. In selecting and executing new drug discovery
programmes, C4X Discovery focuses on high-value disease areas that
are the subject of significant licensing activity and will continue
to also maximise value from opportunistic areas such as addiction
and diabetes. The Company recently signed a licensing agreement
with Indivior for a pre-clinical addiction programme worth up to
$294 million.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
--ENDS----
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEFKCDBPBDDCKD
(END) Dow Jones Newswires
October 19, 2018 11:33 ET (15:33 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024